275 related articles for article (PubMed ID: 17927954)
1. Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208.
Klajnert B; Cortijo-Arellano M; Cladera J; Majoral JP; Caminade AM; Bryszewska M
Biochem Biophys Res Commun; 2007 Dec; 364(1):20-5. PubMed ID: 17927954
[TBL] [Abstract][Full Text] [Related]
2. Influence of dendrimer's structure on its activity against amyloid fibril formation.
Klajnert B; Cortijo-Arellano M; Cladera J; Bryszewska M
Biochem Biophys Res Commun; 2006 Jun; 345(1):21-8. PubMed ID: 16674918
[TBL] [Abstract][Full Text] [Related]
3. Molecular interactions of dendrimers with amyloid peptides: pH dependence.
Klajnert B; Cladera J; Bryszewska M
Biomacromolecules; 2006 Jul; 7(7):2186-91. PubMed ID: 16827586
[TBL] [Abstract][Full Text] [Related]
4. Morphology and secondary structure of stable beta-oligomers formed by amyloid peptide PrP(106-126).
Walsh P; Yau J; Simonetti K; Sharpe S
Biochemistry; 2009 Jun; 48(25):5779-81. PubMed ID: 19476383
[TBL] [Abstract][Full Text] [Related]
5. Conversion of non-fibrillar beta-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation.
Benseny-Cases N; Cócera M; Cladera J
Biochem Biophys Res Commun; 2007 Oct; 361(4):916-21. PubMed ID: 17679138
[TBL] [Abstract][Full Text] [Related]
6. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases.
Klajnert B; Cortijo-Arellano M; Bryszewska M; Cladera J
Biochem Biophys Res Commun; 2006 Jan; 339(2):577-82. PubMed ID: 16310169
[TBL] [Abstract][Full Text] [Related]
7. Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers.
Heegaard PM; Pedersen HG; Flink J; Boas U
FEBS Lett; 2004 Nov; 577(1-2):127-33. PubMed ID: 15527773
[TBL] [Abstract][Full Text] [Related]
8. Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways.
Natalello A; Prokorov VV; Tagliavini F; Morbin M; Forloni G; Beeg M; Manzoni C; Colombo L; Gobbi M; Salmona M; Doglia SM
J Mol Biol; 2008 Sep; 381(5):1349-61. PubMed ID: 18619462
[TBL] [Abstract][Full Text] [Related]
9. Amyloidogenic properties of the prion protein fragment PrP(185-208): comparison with Alzheimer's peptide Abeta(1-28), influence of heparin and cell toxicity.
Cortijo-Arellano M; Ponce J; Durany N; Cladera J
Biochem Biophys Res Commun; 2008 Apr; 368(2):238-42. PubMed ID: 18206983
[TBL] [Abstract][Full Text] [Related]
10. Highly accelerated self-assembly and fibrillation of prion peptides on solid surfaces.
Ku SH; Park CB
Langmuir; 2008 Dec; 24(24):13822-7. PubMed ID: 19053635
[TBL] [Abstract][Full Text] [Related]
11. Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231).
Martins SM; Frosoni DJ; Martinez AM; De Felice FG; Ferreira ST
J Biol Chem; 2006 Sep; 281(36):26121-8. PubMed ID: 16844683
[TBL] [Abstract][Full Text] [Related]
12. Steric zipper of the amyloid fibrils formed by residues 109-122 of the Syrian hamster prion protein.
Lee SW; Mou Y; Lin SY; Chou FC; Tseng WH; Chen CH; Lu CY; Yu SS; Chan JC
J Mol Biol; 2008 May; 378(5):1142-54. PubMed ID: 18423487
[TBL] [Abstract][Full Text] [Related]
13. Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways.
El Moustaine D; Perrier V; Smeller L; Lange R; Torrent J
FEBS J; 2008 May; 275(9):2021-31. PubMed ID: 18355314
[TBL] [Abstract][Full Text] [Related]
14. The interaction of humic substances with the human prion protein fragment 90-231 affects its protease K resistance and cell internalization.
Corsaro A; Anselmi C; Polano M; Aceto A; Florio T; De Nobili M
J Biol Regul Homeost Agents; 2010; 24(1):27-39. PubMed ID: 20385069
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a spontaneously aggregating amyloid-forming variant of human PrP((90-231)) through phage-display screening of variants randomized between residues 101 and 112.
Verma A; Sharma S; Ganguly NK; Majumdar S; Guptasarma P; Luthra-Guptasarma M
Int J Biochem Cell Biol; 2008; 40(4):663-76. PubMed ID: 18023239
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of lactoferrin aggregation and amyloid formation.
Nilsson MR; Dobson CM
Biochemistry; 2003 Jan; 42(2):375-82. PubMed ID: 12525164
[TBL] [Abstract][Full Text] [Related]
17. Molecular properties of complexes formed between the prion protein and synthetic peptides.
Kaneko K; Wille H; Mehlhorn I; Zhang H; Ball H; Cohen FE; Baldwin MA; Prusiner SB
J Mol Biol; 1997 Jul; 270(4):574-86. PubMed ID: 9245588
[TBL] [Abstract][Full Text] [Related]
18. Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site.
Boshuizen RS; Morbin M; Mazzoleni G; Tagliavini F; Meloen RH; Langedijk JP
Amyloid; 2007 Sep; 14(3):205-19. PubMed ID: 17701468
[TBL] [Abstract][Full Text] [Related]
19. Time evolution of the aggregation process of peptides involved in neurodegenerative diseases and preventing aggregation effect of phosphorus dendrimers studied by EPR.
Ottaviani MF; Mazzeo R; Cangiotti M; Fiorani L; Majoral JP; Caminade AM; Pedziwiatr E; Bryszewska M; Klajnert B
Biomacromolecules; 2010 Nov; 11(11):3014-21. PubMed ID: 20958001
[TBL] [Abstract][Full Text] [Related]
20. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein.
Walsh P; Simonetti K; Sharpe S
Structure; 2009 Mar; 17(3):417-26. PubMed ID: 19278656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
